RecruitingPhase 2NCT06660732

Rilonacept in Subjects With Cardiac Sarcoidosis

A RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS)

Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

Mar 5, 2025

Study Type

INTERVENTIONAL

Conditions

Cardiac Sarcoidosis

Summary

The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests rilonacept — an anti-inflammatory injection that blocks a protein called IL-1 — in people with cardiac sarcoidosis, a condition where inflammatory granulomas (clumps of immune cells) form in the heart, causing arrhythmias and heart failure. **You may be eligible if...** - You are between 18 and 80 years old with confirmed cardiac sarcoidosis - You are using effective contraception or are post-menopausal or surgically sterile - Your routine vaccines are up to date **You may NOT be eligible if...** - You have a contraindication to rilonacept or similar drugs - You have a serious active infection - You are pregnant or planning to become pregnant - You have certain other serious medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRilonacept

320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.